Patent ID: 6410563
Filing Date: 2002-06-25
Classification: C07D

Abstract:
A compound represented by Formula (I): or a prodrug, or a pharmaceutically acceptable salt thereof, wherein:S1, S2, and S3 are independently H, â€”OH, halogen, â€”C1-C6alkyl, â€”NO2, â€”CN, or â€”C1-C6alkoxy, wherein the alkyl and alkoxy groups are optionally substituted with 1-5 substituents; wherein each substituent is independently a halogen or OH; R1 is a H, OH, halogen, or carbonyl group, â€”C1-C6alkyl group, -cycloC3-C6alkyl group, â€”C1-C6alkenyl group, â€”C1-C6alkoxy group, aryl group, heteroaryl group, â€”CN, -heterocycloC3-C6alkyl group, -amino group, â€”C1-C6alkylamino group, â€”(C1-C6alkyl)(C1-C6alkyl)amino group, â€”C1-C6alkyl(oxy)C1-C6alkyl group, â€”C(O)NH(aryl) group, â€”C(O)NH(heteroaryl) group, â€”SOnNH(aryl) group, â€”SOnNH(heteroaryl) group, â€”SOnNH(C1-C6alkyl) group, â€”C(O)N(C0-C6alkyl)(C0-C6alkyl) group, â€”NHâ€”SOnâ€”(C1-C6alkyl) group, â€”SOnâ€”(C1-C6alkyl) group, â€”(C1-C6alkyl)â€”Oâ€”C(CN)-dialkylamino group, or â€”(C1-C6alkyl)â€”SOnâ€”(C1-C6alkyl) group, wherein any of the groups is optionally substituted with 1-5 substituents; wherein each substituent is independently a halogen, â€”OH, â€”CN, â€”C1-C6alkyl, -cycloC3-C6alkyl, â€”C(O)(heterocycloC3-C6alkyl), â€”C(O)â€”Oâ€”(C0-C6alkyl), â€”C(O)-aryloxy, â€”C1-C6alkoxy, â€”(C0-C6alkyl)(C0-C6alkyl)amino, cycloalkyloxy, acyl, acyloxy, -cycloC3-C6alkyl, heterocycloC3-C6alkyl, aryl, heteroaryl, carbonyl, carbamoyl, or â€”SOnâ€”(C1-C6alkyl); Ais CH, or C-R4; R2 and R3 independently is an aryl group, heteroaryl group, H, halogen, â€”CN, â€”C1-C6alkyl group, -heterocycloC3-C6alkyl, â€”C1-C6alkoxy group, carbonyl group, carbamoyl group, â€”C(O)OH, â€”(C1-C6alkyl)â€”SOnâ€”(C1-C6alkyl) group, â€”C(O)N(C0-C6alkyl)(C0-C6alkyl) group, or â€”C1-C6alkylacylamino group, wherein any of the groups is optionally substituted with 1-5 substituents, wherein each substituent is independently a halogen, â€”NO2, â€”C(O)OH, â€”CN, N-oxide, â€”OH, or an aryl, heteroaryl, carbonyl, â€”C1-C6alkyl, â€”SOnâ€”(C1-C6alkyl), â€”SOnâ€”(aryl), aryloxy, -heteroaryloxy, C1-C6alkoxy, â€”C(O)-heterocycloC3-C6alkyl, â€”NH-cycloC3-C6alkyl, amino, â€”(C0-C6alkyl)(C0-C6alkyl)amino, or â€”C(O)â€”N(C0-C6alkyl)(C0-C6alkyl) substituent group, wherein each substituent group independently is optionally substituted with â€”OH, C1-C6alkoxy, â€”C1-C6alkyl, -cycloC3-C6alkyl, aryloxy, â€”C(O)OH, â€”C(O)O(C1-C6alkyl), halogen, â€”NO2, â€”CN, â€”SOnâ€”(C1-C6alkyl), or â€”C(O)â€”N(C0-C6alkyl)(C0-C6alkyl); one of R2 and R3 must be an aryl or heteroaryl, optionally substituted; when R2 and R3 are both an aryl or heteroaryl, then R2 and R3 may be optionally connected by a thio, oxy, or (C1-C4alkyl) bridge to form a fused three ring system; R4 is an aryl group, â€”C1-C6alkyl group, heteroaryl group, â€”CN, carbonyl, carbamoyl group, â€”(C1-C6alkyl)â€”SOnâ€”(C1-C6alkyl) group, â€”C(O)N(C0-C6alkyl)(C0-C6alkyl) group, or â€”C1-C6alkylacylamino group, wherein any of the groups is optionally substituted with 1-5 substituents, wherein each substituent is independently a carbonyl, â€”CN, halogen, â€”C(O)(C0-C6alkyl), â€”C(O)O(C0-C6alkyl), â€”C1-C6alkyl, â€”SOnâ€”(C1-C6alkyl), â€”OH, C1-C6alkoxy, or â€”(C0-C6alkyl)(C0-C6alkyl)amino; n is independently 0, 1, or 2; and R2 or R3 may optionally be joined to R4 by a bond to form a ring.